JP2022553378A - 過敏性腸症候群および機能性ディスペプシアを処置するための方法および組成物 - Google Patents

過敏性腸症候群および機能性ディスペプシアを処置するための方法および組成物 Download PDF

Info

Publication number
JP2022553378A
JP2022553378A JP2022523912A JP2022523912A JP2022553378A JP 2022553378 A JP2022553378 A JP 2022553378A JP 2022523912 A JP2022523912 A JP 2022523912A JP 2022523912 A JP2022523912 A JP 2022523912A JP 2022553378 A JP2022553378 A JP 2022553378A
Authority
JP
Japan
Prior art keywords
individual
seq
amino acid
acid sequence
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022523912A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553378A5 (https=
Inventor
ブピンダー シン，
アモル カンボジ，
ヘンリク ラスムッセン，
Original Assignee
アラコス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/018405 external-priority patent/WO2020168271A1/en
Application filed by アラコス インコーポレイテッド filed Critical アラコス インコーポレイテッド
Publication of JP2022553378A publication Critical patent/JP2022553378A/ja
Publication of JP2022553378A5 publication Critical patent/JP2022553378A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022523912A 2019-10-24 2020-10-23 過敏性腸症候群および機能性ディスペプシアを処置するための方法および組成物 Pending JP2022553378A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962925704P 2019-10-24 2019-10-24
US62/925,704 2019-10-24
PCT/US2020/018405 WO2020168271A1 (en) 2019-02-15 2020-02-14 Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis
USPCT/US2020/018405 2020-02-14
US202063067743P 2020-08-19 2020-08-19
US63/067,743 2020-08-19
PCT/US2020/057174 WO2021081411A1 (en) 2019-10-24 2020-10-23 Methods and compositions for treating irritable bowel syndrome and functional dyspepsia

Publications (2)

Publication Number Publication Date
JP2022553378A true JP2022553378A (ja) 2022-12-22
JP2022553378A5 JP2022553378A5 (https=) 2023-10-30

Family

ID=75619380

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022523912A Pending JP2022553378A (ja) 2019-10-24 2020-10-23 過敏性腸症候群および機能性ディスペプシアを処置するための方法および組成物

Country Status (5)

Country Link
US (1) US20220380460A1 (https=)
EP (1) EP4048698A4 (https=)
JP (1) JP2022553378A (https=)
CN (1) CN114829406A (https=)
WO (1) WO2021081411A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL270304B2 (en) * 2017-05-05 2024-07-01 Allakos Inc Methods and preparations for the treatment of inflammatory disorders in the digestive system

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204871A1 (en) * 2017-05-05 2018-11-08 Allakos Inc. Methods and compositions for treating inflammatory gastrointestinal disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ720769A (en) * 2013-12-09 2022-10-28 Allakos Inc Anti-siglec-8 antibodies and methods of use thereof
AU2020223365A1 (en) * 2019-02-15 2021-08-26 Allakos Inc. Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis
KR20220044203A (ko) * 2019-08-02 2022-04-06 알라코스 인크. 항-siglec-8 항체 및 코르티코스테로이드를 투여하는 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204871A1 (en) * 2017-05-05 2018-11-08 Allakos Inc. Methods and compositions for treating inflammatory gastrointestinal disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
日本消化器病学会雑誌, vol. Vol.116，No.7, pp560-569, JPN6024039063, 10 July 2019 (2019-07-10), ISSN: 0005563043 *

Also Published As

Publication number Publication date
US20220380460A1 (en) 2022-12-01
EP4048698A1 (en) 2022-08-31
WO2021081411A1 (en) 2021-04-29
EP4048698A4 (en) 2023-12-06
CN114829406A (zh) 2022-07-29

Similar Documents

Publication Publication Date Title
JP7346304B2 (ja) 炎症性消化器障害を処置するための方法および組成物
US20220135673A1 (en) Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis
JP2023086917A (ja) アレルギー性眼疾患を処置するための方法および組成物
JP2022542472A (ja) 抗ｓｉｇｌｅｃ－８抗体および副腎皮質ステロイド薬を投与する方法
JP2024045612A (ja) 慢性蕁麻疹を処置するための方法および組成物
US20190338027A1 (en) Methods and compositions for treating chronic obstructive pulmonary disorder
JP2023547621A (ja) 抗ｓｉｇｌｅｃ－８抗体製剤
JP2022553378A (ja) 過敏性腸症候群および機能性ディスペプシアを処置するための方法および組成物
WO2024043940A1 (en) Methods and compositions for treating atopic dermatitis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240930

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250401